Features include very common findings: Red blood cell destruction (hemolytic anemia), Fever, and Headache; and common findings: Jaundice, Excessive sweating (hyperhidrosis), Enlarged spleen (splenomegaly), and Low platelet count (thrombocytopenia) and others. 31 total HPO annotations.

Biomarker and diagnostic research for babesiosis has been reported in the published literature.

No approved treatments are currently available for babesiosis. An additional 1 compound holds orphan drug designation.

Orphan Drug Designations

While no drugs are FDA-approved specifically for babesiosis, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.

The following drugs have received orphan drug designation from the FDA for babesiosis. Orphan designation reflects regulatory interest and does not indicate approval for treatment.

Phenotype severity distribution: 3 very common features, 11 common features.

Estimated prevalence: <1 in 1,000,000 (VERY_RARE).

3 clinical trials registered, 3 recruiting. Interventions under study include drug therapy and other interventions. Pipeline includes 2 PHASE2. Research is sponsored by a mix of industry and academic institutions.

377 publications have been identified in PubMed for babesiosis. Kisho has analyzed 53 by research type. Research spans Review / Meta-Analysis (40%), Basic Science / Preclinical (23%), and Epidemiology / Natural History (17%).